For: | Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M, Alexander JS. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases 2019; 7(13): 1571-1581 [PMID: 31367616 DOI: 10.12998/wjcc.v7.i13.1571] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i13/1571.htm |
Number | Citing Articles |
1 |
Dahyeon Lee, Jeong Seop Park, Doyoung Kim, Hyun Sook Hong. Substance P Hinders Bile Acid-Induced Hepatocellular Injury by Modulating Oxidative Stress and Inflammation. Antioxidants 2022; 11(5): 920 doi: 10.3390/antiox11050920
|
2 |
Touraj Ehtezazi, Khalid Rahman, Rhys Davies, Andrew G. Leach. The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease. Journal of Alzheimer's Disease Reports 2023; 7(1): 173 doi: 10.3233/ADR-220071
|
3 |
Daniela Goyes, Christopher J. Danford, Hirsh D. Trivedi, Alan Bonder. Nutrition in Cholestatic Liver Disease. Current Hepatology Reports 2020; 19(1): 1 doi: 10.1007/s11901-020-00511-3
|
4 |
Mariapia Vairetti, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Andrea Ferrigno, Clarissa Berardo. Changes in Glutathione Content in Liver Diseases: An Update. Antioxidants 2021; 10(3): 364 doi: 10.3390/antiox10030364
|
5 |
Halima Sultana, Michio Komai, Hitoshi Shirakawa. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients 2021; 13(8): 2515 doi: 10.3390/nu13082515
|
6 |
Debashree Debasish Das, Nikita Sharma, Pooja A Chawla. Current trends and future perspectives in the treatment of PBC and PSC: A review. Health Sciences Review 2022; 5: 100065 doi: 10.1016/j.hsr.2022.100065
|
7 |
Suzan M. M. Moursi, Eman El Bahaie, Amira Mohamed Abdelhamid, Sherein F. El-sayed. The Role of Apelin and Protamine Sulfate in Bile Duct Ligation-Induced Liver Fibrosis in Rats. Pharmaceutical Chemistry Journal 2023; 57(9): 1339 doi: 10.1007/s11094-023-02995-x
|
8 |
Dandan Song, Pei Zhu, Yankai Dong, Mengchao Wang, Anna Zhao, Hongdong Xia, Yunting Chen, Qingguang Zhou, Lun Xiang, Junyi Zhang, Guangming Luo, Yangjing Luo. Mechanism of crocin I on ANIT-induced intrahepatic cholestasis by combined metabolomics and transcriptomics. Frontiers in Pharmacology 2023; 13 doi: 10.3389/fphar.2022.1088750
|
9 |
Naser-Aldin Lashgari, Danial Khayatan, Nazanin Momeni Roudsari, Saeideh Momtaz, Ahmad Reza Dehpour, Amir Hossein Abdolghaffari. Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway. Naunyn-Schmiedeberg's Archives of Pharmacology 2024; 397(3): 1433 doi: 10.1007/s00210-023-02684-2
|
10 |
Shiman Luo, Meilan Huang, Xiaohua Lu, Mingming Zhang, Huiling Xiong, Xiyue Tan, Xinyu Deng, Wenwen Zhang, Xiao Ma, Jinhao Zeng, Thomas Efferth. Optimized therapeutic potential of Yinchenhao decoction for cholestatic hepatitis by combined network meta-analysis and network pharmacology. Phytomedicine 2024; 129: 155573 doi: 10.1016/j.phymed.2024.155573
|
11 |
Andres Jose Gómez Aldana, Mónica Tapias, Adán Jose Lúquez Mindiola. Colestasis en el adulto: enfoque diagnóstico y terapéutico. Revisión de tema. Revista Colombiana de Gastroenterología 2020; 35(1): 76 doi: 10.22516/25007440.375
|
12 |
Anca D. Petrescu, Sharon DeMorrow. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. Cells 2021; 10(8): 1846 doi: 10.3390/cells10081846
|
13 |
Huan Lan, Ying Zhang, Minqi Fan, Bingxin Wu, Caiyan Wang. Pregnane X receptor as a therapeutic target for cholestatic liver injury. Drug Metabolism Reviews 2023; 55(4): 371 doi: 10.1080/03602532.2023.2248680
|
14 |
Shelly C. Lu. Dysregulation of glutathione synthesis in liver disease. Liver Research 2020; 4(2): 64 doi: 10.1016/j.livres.2020.05.003
|
15 |
Guodong Li, Yanjiao Xu, Qianyan Gao, Sheng Guo, Yue Zu, Ximin Wang, Congyi Wang, Chengliang Zhang, Dong Liu. Ginsenosides Restore Lipid and Redox Homeostasis in Mice with Intrahepatic Cholestasis through SIRT1/AMPK Pathways. Nutrients 2022; 14(19): 3938 doi: 10.3390/nu14193938
|